Skip to main content

AbbVie rheumatoid arthritis drug succeeds in late stage trial

AbbVie Inc on Tuesday said its experimental rheumatoid arthritis (RA) treatment showed significant improvement in physical function, pain and quality of life compared with the commonly prescribed generic drug methotrexate in a late stage clinical trial.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.